Australia Markets closed

Why this ASX cannabis share crashed 13% lower on Thursday

James Mickleboro
medical marijuana, cannabis, pot, drug, medical

The AusCann Group Holdings Ltd (ASX: AC8) share price certainly was out of form on Thursday.

The medicinal cannabis company’s shares were the worst performers on the All Ordinaries with a decline of 13% to 23.5 cents.

Why did the AusCann share price tumble lower?

There appears to have been a couple of catalysts for this sizeable share price decline.

The first was profit taking from traders following some very strong gains this week.

For example, prior to yesterday’s decline, AusCann’s shares were up almost 50% since the start of the week.

Investors had been fighting to get hold of the company’s shares following an update on its proprietary cannabinoid-based hard-shell capsules.

That update revealed that AusCann has completed the manufacturing and testing of the hard-shell capsules and released them for clinical evaluation. The goal of the clinical evaluation is to provide key exposure information to inform dose selection.

This essentially means that it may not be long until AusCann is finally generating revenues. It is targeting hard-shell capsules availability for patients in Australia during the first half of calendar year 2020.

AusCann CEO, Mr Ido Kanyon, explained: “We remain focused on making AusCann’s capsules available for prescription to patients in Australia during the first half of 2020. Our goal is to provide high-quality medicine and to obtain detailed, data-driven evaluations regarding the outcomes of AusCann’s pharmaceutical treatment. These results will build the clinical evidence supporting the unique benefits of AusCann’s capsules necessary to open a large market for the Company.”

Increasing competition.

Another potential catalyst for the share price weakness was an update out of rival Cann Group Ltd (ASX: CAN) on Thursday.

Cann Group’s update revealed that it is also close to a commercial release of its own products.

According to the release, the first commercial medicinal cannabis product from its Australian-based cultivation operations has been packed by IDT Australia Limited (ASX: IDT) under cGMP conditions. It will now undergo stability testing ahead of release in the first quarter of 2020.

These products join a growing number of medicinal cannabis products that have recently been commercialised in Australia.

The post Why this ASX cannabis share crashed 13% lower on Thursday appeared first on Motley Fool Australia.

Not sure about cannabis shares? Then check out these highly rated growth shares.

NEW. Analyst Names the Best Growth Shares to Buy in 2020….

Our Motley Fool experts have just released a brand new FREE report, detailing 5 dirt cheap shares that you can buy today.

One stock is an Australian internet darling with a rock solid reputation and an exciting new business line that promises years (or even decades) of growth… while trading at an ultra-low price…

Another is a diversified conglomerate trading near a 52-week low all while offering a 2.8% fully franked yield...

Plus 3 more cheap bets that could position you to profit over the next 12 months!

See for yourself now. Simply click the link below to scoop up your FREE copy and discover all 5 shares. But you will want to hurry – this free report is available for a brief time only.


More reading

Motley Fool contributor James Mickleboro has no position in any of the stocks mentioned. The Motley Fool Australia has no position in any of the stocks mentioned. We Fools may not all hold the same opinions, but we all believe that considering a diverse range of insights makes us better investors. The Motley Fool has a disclosure policy. This article contains general investment advice only (under AFSL 400691). Authorised by Scott Phillips.

The Motley Fool's purpose is to help the world invest, better. Click here now for your free subscription to Take Stock, The Motley Fool's free investing newsletter. Packed with stock ideas and investing advice, it is essential reading for anyone looking to build and grow their wealth in the years ahead. This article contains general investment advice only (under AFSL 400691). Authorised by Bruce Jackson. 2019